Other studies indicate that constitutive mTOR signaling activation occurring upon TSC1 or TSC2 defects leads to accumulation of p53 in TSC tumors, and the efficacy of mTOR inhibitors may depend on p53 status [42]. The gene discussed is TP53; the disease is tuberous sclerosis.